Physician profile
Lance James Doeden
NPI 1952659773
$13,462.96
in general payments reported to CMS, 2019-2025
14 companies · $4,401 in 2025
The $4,401 reported for 2025 was more than what 90% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $386 · 2021: $2,434 · 2022: $1,114 · 2023: $2,616 · 2024: $2,024 · 2025: $4,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,087 · Travel and Lodging: $3,155 · Consulting Fee: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,086.52 |
| Travel and Lodging | $3,155.31 |
| Consulting Fee | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,839.10 | 2019-2024 | Senza |
| Medtronic, INC. | $2,354.95 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Kyphon Express II Kyphopak Tray |
| Abbott Laboratories | $1,933.33 | 2024-2025 | Proclaim, Eterna, Octrode |
| Pfizer INC. | $1,875.07 | 2023-2025 | |
| Boston Scientific Corporation | $1,714.24 | 2019-2025 | Intracept, Intracept Rf Probe, Superion Indirect Decompression System |
| Relievant Medsystems, INC. | $1,412.53 | 2021-2023 | Intracept |
| Globus Medical, INC. | $655.42 | 2025 | Senza, Vyrsa Fix, Vyrsa V1 |
| Vertos Medical, INC. | $207.22 | 2021-2023 | Mild Device Kit |
| Tersera Therapeutics LLC | $119.43 | 2023-2025 | Prialt |
| Spr Therapeutics, INC | $101.03 | 2023 | Sprint Pns System |
| Abbvie INC. | $94.50 | 2022-2025 | Ubrelvy, Qulipta |
| Nalu Medical, INC. | $70.94 | 2022-2024 | Nalu Neurostimulation System |
| Vertex Pharmaceuticals Incorporated | $54.45 | 2024-2025 | |
| Medtronic USA, INC. | $30.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Doeden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.